Goal
Rapidly extend telomeres to prevent or treat hypertension and other age-related conditions
Problem
Telomere shortening that contributes to hypertension, heart failure, immunosenescence and vascular dementia
Concept Summary
A transient, non-integrating mRNA drug containing modified nucleosides (pseudouridine, 5-methylcytidine) encodes telomerase. Delivered intravenously (e.g., via autologous exosomes), it expresses telomerase for a few days, extending telomeres in six days by an amount equivalent to 15 years of normal aging. The brief exposure preserves normal anti-cancer telomere-shortening mechanisms and avoids genome integration.
Principles
- Modified nucleoside mRNA to reduce immunogenicity
- Transient expression of telomerase
- Exosome-mediated intravenous delivery
Scientific Domains
Materials
- mRNA
- Pseudouridine
- 5-methylcytidine (m5C)
- Exosomes (autologous)
- Cap analogs and poly(A) tails
Mechanisms of Action
- Telomerase reverse transcriptase expression
- Telomere elongation in endothelial and progenitor cells
- Prevention of cellular senescence
Applications
- Treatment of hypertension
- Therapy for age-related cardiovascular disease
- Potential use in immunosenescence and vascular dementia
Claimed Performance
Extends telomeres in six days by the amount lost over 15 years of normal human aging; prevents hypertension in short-telomere mouse model.
Experimental Evidence
In the short-telomere mTERC-null mouse model of hypertension, intravenous delivery of the mRNA drug extended endothelial telomeres and prevented endothelial senescence, reducing hypertension-related phenotypes.
Replication Status
Demonstrated in mouse model; human studies not yet performed.
Limitations
- Transient expression requires precise dosing
- Delivery vehicle optimization still needed
- Long-term safety (tumorigenesis) not yet established
Red Flags
- Potential for tumor formation if telomerase is over-expressed
- Regulatory hurdles for gene-therapy-type RNA drugs
